by Allogeneic stem cell transplantation involves using healthy stem cells from a donor rather than the patient’s own stem cells. It is commonly used to treat cancers like leukemia and lymphoma as well as other serious blood disorders where the bone marrow and immune system have been damaged by disease, high-dose chemotherapy or radiation therapy. The process involves collection of healthy stem cells from bone marrow, peripheral blood or umbilical cord blood of a donor whose tissue type closely matches that of the patient. These donated stem cells are then transfused into the patient after chemotherapy or radiation therapy to destroy any remaining cancer cells or immune cells. The transplantation aims to replace the damaged or destroyed bone marrow with healthy stem cells which then rebuild the patient’s immune system.
The global Allogeneic Stem Cell Transplantation Market is estimated to be valued at US$ 3.9 Bn in 2023 and is expected to exhibit a CAGR of 6.5% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends
One of the key trends in the allogeneic stem cell transplantation market is the increasing adoption of umbilical cord blood as a stem cell source. Umbilical cord blood is rich in hematopoietic stem cells that can be transplanted to patients in need of bone marrow transplantation. Compared to bone marrow and peripheral blood, cord blood has certain advantages like immediate availability, reduced risk of infection transmission, and lower chances of graft versus host disease. With over 30,000 cord blood units in public banks worldwide, doctors are increasingly opting for cord blood transplantation for treatment of various conditions. This is expected to drive significant growth of the overall market during the forecast period.
Porter’s Analysis
Threat of new entrants: The allogeneic stem cell transplantation market requires high capital investments and strict regulatory approvals, lowering the threat of new entrants.
Bargaining power of buyers: The buyers have moderate bargaining power due to the availability of alternative treatment options for diseases treatable by stem cell transplant.
Bargaining power of suppliers: The suppliers have low-to-moderate bargaining power due to the presence of well-established players and availability of substitutes.
Threat of new substitutes: The threat of substitutes is low as allogeneic stem cell transplantation provides distinct clinical benefits over other treatment alternatives.
Competitive rivalry: The market is highly competitive due to the presence of key global players.
Key Takeaways
The global Allogeneic Stem Cell Transplantation Market is expected to witness high growth.
Regional analysis: The Asia Pacific is anticipated to grow at the highest CAGR during the forecast period. China, India, and Japan dominate the APAC market due to the increasing number of stem cell transplantation procedures, stem cell tourism, rising geriatric population, and improved healthcare infrastructure.
Key players: Key players operating in the allogeneic stem cell transplantation market are Wacker Neuson SE, Sany Heavy Industry Co. Ltd, Volvo Construction Equipment, Wirtgen Group, Caterpillar Inc., Atlas Copco, Terex Corporation, Zoomlion Heavy Industries Science & Technology Co Ltd, Fayat Group, BOMAG GmbH, and XCMG Co. Ltd. Wacker Neuson SE held the largest market share in 2023.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
